Arafa is indicated in- Relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis Treatment of primary dysmenorrhea Control of mild to moderate pain generally and particularly when pain is associated with inflammation Reduction of fever Dental and period pain Relief of backache Rheumatic pain Muscular pain
Ibuprofen has a high level of anti-inflammatory, anti-pyretic, and analgesic activity. The analgesic effects of Ibuprofen are due to both a peripheral and a central effect. Ibuprofen is a potent inhibitor of the enzyme cyclooxygenase, which thus results in a marked reduction in prostaglandin synthesis. Ibuprofen also inhibits the synthesis of some lipo-oxygenase products. Ibuprofen thus quickly relieves pain and stiffness, reduces swelling, and improves the movement of different joints of arthritis sufferers.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Adults, the elderly and children & adolescents between 12 and 18 years Initially one (300 mg) or two (600 mg) Ibuprofen SR capsules should be taken twice daily. Not more than 4 capsules are to be taken in 24 hours. Ibuprofen SR capsule is not recommended for children below 12 years of age. Ibuprofen Suspension : Children- 3-6 months (body-weight over 5 kg): 1/2 tsp (2.5 ml) 3 times daily 6 months-1 year: 0.5 tsp (2.5 ml) 3-4 times daily 1-4 years: 1 tsp (5 ml) 3 times daily 4-7 years: 1.5 tsp (7.5 ml) 3 times daily 7-10 years: 2 tsp (10 ml) 3 times daily 10-12 years: 3 tsp (15 ml) 3 times daily Not recommended for children weighing less than 5 kg. In juvenile rheumatoid arthritis; up to 30-40 mg/kg of body weight daily in 3-4 divided doses may be taken.
The most common side effects are headache, somnolence, vertigo, fatigue, agitation, dizziness, insomnia, irritability and gastrointestinal ulcer.
It is contraindicated in patients with known hypersensitivity to ibuprofen or any other components of this product. It is also contraindicated in patients with history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy, active or history of recurrent peptic ulcer/haemorrhage, severe renal failure or severe hepatic failure, severe heart failure (NYHA Class IV), last trimester of pregnancy, significant dehydration and cerebrovascular or other active bleeding.
Caution should be taken in concomitant use with the medications which could increase the risk of ulceration or bleeding. Concomitant use with acetylsalicylic acid is not recommended. Co-administration with other NSAIDs and high doses of methotrexate should be avoided. Caution should be taken in concomitant use with ACE inhibitors, diuretics, lithium, anti-platelet agents, warfarin, aminoglycosides, corticosteroids, cyclosporin, tacrolimus, mifepristone, quinolone, zidovudine, voriconazole and fluconazole.
Patients on long term therapy with Arafa require ocular monitoring at regular intervals, as changes in ocular function have been reported. Patients with SLE are more likely than others to develop hypersensitivity to Arafa. Arafa should be prescribed with caution in patients with asthma.